GHRP-2 Complete Pharmacology: GH Release, Appetite, Cardiovascular, and Clinical Applications
This comprehensive pharmacological review of GHRP-2 (KP-102/pralmorelin) covers its potent GH-releasing activity, appetite stimulation, cardiovascular effects, receptor pharmacology, and clinical applications across GH deficiency and diagnostic testing.
Quick Facts
What This Study Found
GHRP-2 (KP-102/pralmorelin) demonstrates potent GH-releasing activity through dual hypothalamic-pituitary mechanisms, with characterized appetite, cardiovascular, and diagnostic applications — a comprehensive pharmacological profile.
Key Numbers
How They Did This
Comprehensive pharmacological review covering GHRP-2 receptor binding, in-vitro/in-vivo GH-releasing activity, appetite effects, cardiovascular properties, and clinical trial data.
Why This Research Matters
GHRP-2 is one of the most widely used GH secretagogues in research and clinical testing. This definitive pharmacological reference is essential for anyone working with this compound.
The Bigger Picture
GHRP-2 represents the gold standard peptide GH secretagogue. Its comprehensive pharmacological characterization serves as the benchmark against which other GH peptides are compared.
What This Study Doesn't Tell Us
Review from 2004. Some clinical applications were still in development.
Questions This Raises
- ?Is GHRP-2 the most potent available GH secretagogue?
- ?How does it compare to ipamorelin for selectivity?
- ?Should GHRP-2 be the reference standard for GH secretagogue comparison?
Trust & Context
- Key Stat:
- Gold standard GHS GHRP-2 is one of the most potent and comprehensively characterized GH secretagogues — the benchmark for the field
- Evidence Grade:
- Moderate evidence from a comprehensive pharmacological review covering extensive preclinical and clinical data.
- Study Age:
- Published in 2004. GHRP-2 (pralmorelin) is approved for diagnostic GH testing in some countries and widely used in research.
- Original Title:
- Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.
- Published In:
- Arzneimittel-Forschung, 54(12), 857-67 (2004)
- Authors:
- Doi, Naomi, Hirotani, Chiharu, Ukai, Kiyoharu, Shimada, Osafumi, Okuno, Tadashi, Kurasaki, Shigeru, Kiyofuji, Takeshi, Ikegami, Reiko, Futamata, Machiko, Nakagawa, Terutake, Ase, Katsuhiko, Chihara, Kazuo
- Database ID:
- RPEP-00905
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is GHRP-2?
One of the most potent synthetic growth hormone-releasing peptides, also known as KP-102 or pralmorelin. It stimulates GH release through both brain and pituitary mechanisms and is used for GH deficiency diagnosis.
How does it compare to other GH peptides?
GHRP-2 is among the most potent GH releasers but is less selective than ipamorelin (which avoids cortisol/prolactin increases). It's the benchmark against which other GH secretagogues are measured.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00905APA
Doi, Naomi; Hirotani, Chiharu; Ukai, Kiyoharu; Shimada, Osafumi; Okuno, Tadashi; Kurasaki, Shigeru; Kiyofuji, Takeshi; Ikegami, Reiko; Futamata, Machiko; Nakagawa, Terutake; Ase, Katsuhiko; Chihara, Kazuo. (2004). Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.. Arzneimittel-Forschung, 54(12), 857-67.
MLA
Doi, Naomi, et al. "Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.." Arzneimittel-Forschung, 2004.
RethinkPeptides
RethinkPeptides Research Database. "Pharmacological characteristics of KP-102 (GHRP-2), a potent..." RPEP-00905. Retrieved from https://rethinkpeptides.com/research/doi-2004-pharmacological-characteristics-of-kp102
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.